Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2012

01-06-2012 | Original Research

Medical Center Characteristics Associated with PSA Screening in Elderly Veterans with Limited Life Expectancy

Authors: Cynthia So, MPH, Katharine A. Kirby, MS, Kala Mehta, DSc, MPH, Richard M. Hoffman, MD, MPH, Adam A. Powell, PhD, MBA, Stephen J. Freedland, MD, Brenda Sirovich, MD, Elizabeth M. Yano, PhD, MSPH, Louise C. Walter, MD

Published in: Journal of General Internal Medicine | Issue 6/2012

Login to get access

ABSTRACT

BACKGROUND

Although guidelines recommend against prostate-specific antigen (PSA) screening in elderly men with limited life expectancy, screening is common.

OBJECTIVE

We sought to identify medical center characteristics associated with screening in this population.

DESIGN/PARTICIPANTS

We conducted a prospective study of 622,262 screen-eligible men aged 70+ seen at 104 VA medical centers in 2003.

MAIN MEASURES

Primary outcome was the percentage of men at each center who received PSA screening in 2003, based on VA data and Medicare claims. Men were stratified into life expectancy groups ranging from favorable (age 70–79 with Charlson score = 0) to limited (age 85+ with Charlson score ≥1 or age 70+ with Charlson score ≥4). Medical center characteristics were obtained from the 1999–2000 VA Survey of Primary Care Practices and publicly available VA data sources.

KEY RESULTS

Among 123,223 (20%) men with limited life expectancy, 45% received PSA screening in 2003. Across 104 VAs, the PSA screening rate among men with limited life expectancy ranged from 25-79% (median 43%). Higher screening was associated with the following center characteristics: no academic affiliation (50% vs. 43%, adjusted RR = 1.14, 95% CI 1.04–1.25), a ratio of midlevel providers to physicians ≥3:4 (55% vs. 45%, adjusted RR = 1.20, 95% CI 1.09–1.32) and location in the South (49% vs. 39% in the West, adjusted RR = 1.25, 95% CI 1.12–1.40). Use of incentives and high scores on performance measures were not independently associated with screening. Within centers, the percentages of men screened with limited and favorable life expectancies were highly correlated (r = 0.90).

CONCLUSIONS

Substantial practice variation exists for PSA screening in older men with limited life expectancy across VAs. The high center-specific correlation of screening among men with limited and favorable life expectancies indicates that PSA screening is poorly targeted according to life expectancy.
Literature
1.
go back to reference Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003;53:27–43.PubMedCrossRef Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the early detection of cancer, 2003. CA Cancer J Clin. 2003;53:27–43.PubMedCrossRef
2.
go back to reference Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182(5):2232–2241.PubMedCrossRef Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182(5):2232–2241.PubMedCrossRef
3.
go back to reference Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2002;137:915–6. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2002;137:915–6.
4.
go back to reference Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011;29(4):355–361.PubMedCrossRef Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011;29(4):355–361.PubMedCrossRef
5.
go back to reference Stamatiou K, Alevizos A, Mariolis A, et al. Do clinically insignificant tumors of the prostate exist? Urol Int. 2008;81(4):379–382.PubMedCrossRef Stamatiou K, Alevizos A, Mariolis A, et al. Do clinically insignificant tumors of the prostate exist? Urol Int. 2008;81(4):379–382.PubMedCrossRef
6.
go back to reference Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med. 2004;38(6):732–744.PubMedCrossRef Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med. 2004;38(6):732–744.PubMedCrossRef
7.
go back to reference Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296(19):2336–2342.PubMedCrossRef Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296(19):2336–2342.PubMedCrossRef
8.
go back to reference Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003;289(11):1414–1420.PubMedCrossRef Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA. 2003;289(11):1414–1420.PubMedCrossRef
9.
go back to reference Bynum J, Song Y, Fisher E. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare. J Am Geriatr Soc. 2010;58(4):674–680.PubMedCrossRef Bynum J, Song Y, Fisher E. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare. J Am Geriatr Soc. 2010;58(4):674–680.PubMedCrossRef
10.
go back to reference Lu-Yao G, Stukel TA, Yao SL. Prostate-specific antigen screening in elderly men. J Natl Cancer Inst. 2003;95(23):1792–1797.PubMedCrossRef Lu-Yao G, Stukel TA, Yao SL. Prostate-specific antigen screening in elderly men. J Natl Cancer Inst. 2003;95(23):1792–1797.PubMedCrossRef
11.
go back to reference Li J, Zhao G, Pollack LA, Smith JL, Joseph DA. Use of the prostate-specific antigen test among men aged 75 years or older in the United States: 2006 Behavioral Risk Factor Surveillance System. Prev Chronic Dis. 2010;7(4):A84.PubMed Li J, Zhao G, Pollack LA, Smith JL, Joseph DA. Use of the prostate-specific antigen test among men aged 75 years or older in the United States: 2006 Behavioral Risk Factor Surveillance System. Prev Chronic Dis. 2010;7(4):A84.PubMed
12.
go back to reference Freeman JL, Klabunde CN, Schussler N, Warren JL, Virnig BA, Cooper GS. Measuring breast, colorectal, and prostate cancer screening with Medicare claims data. Med Care. 2002;40(suppl IV):36–42. Freeman JL, Klabunde CN, Schussler N, Warren JL, Virnig BA, Cooper GS. Measuring breast, colorectal, and prostate cancer screening with Medicare claims data. Med Care. 2002;40(suppl IV):36–42.
13.
go back to reference Yano EM, Simon B, Canelo I, Mittman B, Rubenstein LV. 1999 VHA Survey of Primary Care Practices, Technical Monograph #00-MC12. Sepulveda, CA: VA HSR&D Center of Excellence for the Study of Healthcare Provider Behavior; 2000. Yano EM, Simon B, Canelo I, Mittman B, Rubenstein LV. 1999 VHA Survey of Primary Care Practices, Technical Monograph #00-MC12. Sepulveda, CA: VA HSR&D Center of Excellence for the Study of Healthcare Provider Behavior; 2000.
14.
go back to reference Yano EM, Soban LM, Parkerton PH, Etzioni DA. Primary care practice organization influences colorectal cancer screening performance. Health Serv Res. 2007;42(3, pt 1):1130–1149.PubMedCrossRef Yano EM, Soban LM, Parkerton PH, Etzioni DA. Primary care practice organization influences colorectal cancer screening performance. Health Serv Res. 2007;42(3, pt 1):1130–1149.PubMedCrossRef
15.
go back to reference Federal Practitioner. 2003 Directory: VA and DoD Health Care Facilities. Chatham, NJ: Quadrant HealthCom Inc; 2003. Federal Practitioner. 2003 Directory: VA and DoD Health Care Facilities. Chatham, NJ: Quadrant HealthCom Inc; 2003.
17.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.PubMedCrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.PubMedCrossRef
18.
go back to reference Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285(21):2750–2756.PubMedCrossRef Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285(21):2750–2756.PubMedCrossRef
19.
go back to reference Kistler CE, Kirby KA, Lee D, Casadei MA, Walter LC. Long-term outcomes following positive fecal occult blood test results in older adults: benefits and burdens. Arch Intern Med. 2011;171(15):1344–1351. Epub 2011 May 9.PubMedCrossRef Kistler CE, Kirby KA, Lee D, Casadei MA, Walter LC. Long-term outcomes following positive fecal occult blood test results in older adults: benefits and burdens. Arch Intern Med. 2011;171(15):1344–1351. Epub 2011 May 9.PubMedCrossRef
20.
go back to reference McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157(10):940–943.PubMedCrossRef McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157(10):940–943.PubMedCrossRef
21.
go back to reference Little RJA, Rubin DB. Statistical Analysis with Missing Data. 2nd ed. New York: John Wiley & Sons; 2002. Little RJA, Rubin DB. Statistical Analysis with Missing Data. 2nd ed. New York: John Wiley & Sons; 2002.
22.
go back to reference Shaw PA, Etzioni R, Zeliadt SB, et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004;160(11):1059–1069.PubMedCrossRef Shaw PA, Etzioni R, Zeliadt SB, et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol. 2004;160(11):1059–1069.PubMedCrossRef
23.
go back to reference Henderson JA, Espey DK, Jim MA, German RR, Shaw KM, Hoffman RM. Prostate cancer incidence among American Indian and Alaska Native men, US, 1999–2004. Cancer. 2008;113((5)(suppl)):1203–1212.PubMedCrossRef Henderson JA, Espey DK, Jim MA, German RR, Shaw KM, Hoffman RM. Prostate cancer incidence among American Indian and Alaska Native men, US, 1999–2004. Cancer. 2008;113((5)(suppl)):1203–1212.PubMedCrossRef
24.
go back to reference Sirovich B, Gallagher PM, Wennberg DE, Fisher ES. Discretionary decision making by primary care physicians and the cost of U.S. Health care. Health Aff (Millwood). 2008;27(3):813–823.CrossRef Sirovich B, Gallagher PM, Wennberg DE, Fisher ES. Discretionary decision making by primary care physicians and the cost of U.S. Health care. Health Aff (Millwood). 2008;27(3):813–823.CrossRef
25.
go back to reference Cooper MM. The Dartmouth Atlas of Health Care: what is it telling us? Health Syst Rev. 1996;29(3):44–45. 47.PubMed Cooper MM. The Dartmouth Atlas of Health Care: what is it telling us? Health Syst Rev. 1996;29(3):44–45. 47.PubMed
26.
go back to reference Collins MM, Barry MJ. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate. JAMA. 1996;276(24):1976–1979.PubMedCrossRef Collins MM, Barry MJ. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate. JAMA. 1996;276(24):1976–1979.PubMedCrossRef
27.
go back to reference Purvis Cooper C, Merritt TL, Ross LE, John LV, Jorgensen CM. To screen or not to screen, when clinical guidelines disagree: primary care physicians’ use of the PSA test. Prev Med. 2004;38:181–191.CrossRef Purvis Cooper C, Merritt TL, Ross LE, John LV, Jorgensen CM. To screen or not to screen, when clinical guidelines disagree: primary care physicians’ use of the PSA test. Prev Med. 2004;38:181–191.CrossRef
28.
go back to reference Anthony DL, Herndon MB, Gallagher PM, et al. How much do patients’ preferences contribute to resource use? Health Aff (Millwood). 2009;28(3):864–873.CrossRef Anthony DL, Herndon MB, Gallagher PM, et al. How much do patients’ preferences contribute to resource use? Health Aff (Millwood). 2009;28(3):864–873.CrossRef
29.
go back to reference Voss JD, Schectman JM. Prostate cancer screening practices and beliefs. J Gen Intern Med. 2001;16(12):831–837.PubMedCrossRef Voss JD, Schectman JM. Prostate cancer screening practices and beliefs. J Gen Intern Med. 2001;16(12):831–837.PubMedCrossRef
30.
go back to reference Austin OJ, Valente S, Hasse LA, Kues JR. Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians. Arch Fam Med. 1997;6(5):453–458.PubMedCrossRef Austin OJ, Valente S, Hasse LA, Kues JR. Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians. Arch Fam Med. 1997;6(5):453–458.PubMedCrossRef
31.
go back to reference Hicks RJ, Hamm RM, Bemben DA. Prostate cancer screening. What family physicians believe is best. Arch Fam Med. 1995;4(4):317–322.PubMedCrossRef Hicks RJ, Hamm RM, Bemben DA. Prostate cancer screening. What family physicians believe is best. Arch Fam Med. 1995;4(4):317–322.PubMedCrossRef
32.
go back to reference Tasian GE, Cooperberg MR, Cowan JE, et al. Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. Epub 2010 Tasian GE, Cooperberg MR, Cowan JE, et al. Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. Epub 2010
33.
go back to reference Hartz A, Lucas J, Cramm T, et al. Physician surveys to assess customary care in medical malpractice cases. J Gen Intern Med. 2002;17(7):546–555.PubMedCrossRef Hartz A, Lucas J, Cramm T, et al. Physician surveys to assess customary care in medical malpractice cases. J Gen Intern Med. 2002;17(7):546–555.PubMedCrossRef
34.
go back to reference Menees SB, Patel DA, Dalton V. Colorectal cancer screening practices among obstetrician/gynecologists and nurse practitioners. J Womens Health (Larchmt). 2009;18(8):1233–1238.CrossRef Menees SB, Patel DA, Dalton V. Colorectal cancer screening practices among obstetrician/gynecologists and nurse practitioners. J Womens Health (Larchmt). 2009;18(8):1233–1238.CrossRef
35.
go back to reference Hudson SV, Ohman-Strickland P, Cunningham R, Ferrante JM, Hahn K, Crabtree BF. The effects of teamwork and system support on colorectal cancer screening in primary care practices. Cancer Detect Prev. 2007;31(5):417–423.PubMedCrossRef Hudson SV, Ohman-Strickland P, Cunningham R, Ferrante JM, Hahn K, Crabtree BF. The effects of teamwork and system support on colorectal cancer screening in primary care practices. Cancer Detect Prev. 2007;31(5):417–423.PubMedCrossRef
36.
go back to reference Kerfoot BP, Holmberg EF, Lawler EV, Krupat E, Conlin PR. Practitioner-level determinants of inappropriate prostate-specific antigen screening. Arch Intern Med. 2007;167(13):1367–1372.PubMedCrossRef Kerfoot BP, Holmberg EF, Lawler EV, Krupat E, Conlin PR. Practitioner-level determinants of inappropriate prostate-specific antigen screening. Arch Intern Med. 2007;167(13):1367–1372.PubMedCrossRef
37.
go back to reference Walter LC, Davidowitz NP, Heineken PA, Covinsky KE. Pitfalls of converting practice guidelines into quality measures: lessons learned from a VA performance measure. JAMA. 2004;291(20):2466–2470.PubMedCrossRef Walter LC, Davidowitz NP, Heineken PA, Covinsky KE. Pitfalls of converting practice guidelines into quality measures: lessons learned from a VA performance measure. JAMA. 2004;291(20):2466–2470.PubMedCrossRef
38.
go back to reference Casalino LP. The unintended consequences of measuring quality on the quality of medical care. N Engl J Med. 1999;341(15):1147–1150.PubMedCrossRef Casalino LP. The unintended consequences of measuring quality on the quality of medical care. N Engl J Med. 1999;341(15):1147–1150.PubMedCrossRef
39.
go back to reference Fisher M. Is prostate-specific antigen (PSA) screening indicated for any subgroup of men? J Fam Pract. 2002;51(2):113.PubMed Fisher M. Is prostate-specific antigen (PSA) screening indicated for any subgroup of men? J Fam Pract. 2002;51(2):113.PubMed
41.
go back to reference Hudson SV, Ohman-Strickland P, Ferrante JM, Lu-Yao G, Orzano AJ, Crabtree BF. Prostate-specific antigen testing among the elderly in community-based family medicine practices. J Am Board Fam Med. 2009;22(3):257–265.PubMedCrossRef Hudson SV, Ohman-Strickland P, Ferrante JM, Lu-Yao G, Orzano AJ, Crabtree BF. Prostate-specific antigen testing among the elderly in community-based family medicine practices. J Am Board Fam Med. 2009;22(3):257–265.PubMedCrossRef
42.
go back to reference Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med. 1996;124(6):577–584.PubMed Welch HG, Albertsen PC, Nease RF, Bubolz TA, Wasson JH. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med. 1996;124(6):577–584.PubMed
43.
go back to reference Volk RJ, Hawley ST, Kneuper S, et al. Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med. 2007;33(5):428–434.PubMedCrossRef Volk RJ, Hawley ST, Kneuper S, et al. Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med. 2007;33(5):428–434.PubMedCrossRef
44.
go back to reference Frosch DL, Kaplan RM, Felitti VJ. A randomized controlled trial comparing internet and video to facilitate patient education for men considering the prostate specific antigen test. J Gen Intern Med. 2003;18(10):781–787.PubMedCrossRef Frosch DL, Kaplan RM, Felitti VJ. A randomized controlled trial comparing internet and video to facilitate patient education for men considering the prostate specific antigen test. J Gen Intern Med. 2003;18(10):781–787.PubMedCrossRef
45.
go back to reference Bellizzi KM, Breslau ES, Burness A, Waldron W. Still screening after all these years. Prevalence and correlates of cancer screening in older racially diverse adults. Arch Intern Med. Forthcoming 2011. Bellizzi KM, Breslau ES, Burness A, Waldron W. Still screening after all these years. Prevalence and correlates of cancer screening in older racially diverse adults. Arch Intern Med. Forthcoming 2011.
Metadata
Title
Medical Center Characteristics Associated with PSA Screening in Elderly Veterans with Limited Life Expectancy
Authors
Cynthia So, MPH
Katharine A. Kirby, MS
Kala Mehta, DSc, MPH
Richard M. Hoffman, MD, MPH
Adam A. Powell, PhD, MBA
Stephen J. Freedland, MD
Brenda Sirovich, MD
Elizabeth M. Yano, PhD, MSPH
Louise C. Walter, MD
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 6/2012
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-011-1945-9

Other articles of this Issue 6/2012

Journal of General Internal Medicine 6/2012 Go to the issue

Healing Arts: Materia Medica

Access to Care: Too Much or Not Enough?

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.